JERSEY CITY, N.J., Feb. 3, 2022 /PRNewswire/ -- The newly published report titled "Global Gene Therapy for Blood Disorders Market– By Trends, Industry Competition Analysis, Pipeline Analysis/Clinical Trial, Revenue (US$ Billions) and Forecast Till 2030." features in-depth analysis and an extensive market study, exploring its significant upcoming years industry factors.
According to the latest gene therapy industry market research report, the global gene therapy for blood disorders market size was valued at US$ 1.13 Billion in 2021, and it is expected to reach US$ 5.79 Billion in 2030, recording a promising CAGR of 21.6 % during the forecast period of 2022 to 2030.
Get the Sample Report: https://www.insightaceanalytic.com/request-sample/1156
Genetic therapy is used to alter human genes for the treatment of diseases. It has excellent potential for treating rare blood diseases such as sickle cell disease and hemophilia. Various biopharma companies are switching to gene-editing technique, CRISPR-Cas9, as a tool to fight rare diseases. CRISPR Therapeutics is conducting a phase I / II trial of CRISPR / Cas9-based genetic therapy, CTX001, to treat sickle cell disease in partnership with Vertex Pharmaceuticals. The increasing prevalence of genetic and blood disorders, high demand for personalized medicine, increased healthcare expenditure, increased R&D activities to develop promising genetic therapies for hematology are expected to boost the market growth in the upcoming years. According to a study published in the PLOS Medicine Journal, cases of sickle cell anemia are projected to increase by about 30% worldwide by 2050. Therefore, the increase in rare hematology disorders is a major driving factor in this market.
However, the high cost of gene therapy treatment and the potential side effects of the therapies are expected to hinder the penetration of gene therapy treatment during the forecast period.
Prview for Detailed ToC: https://www.insightaceanalytic.com/report/global-gene-therapy-for-blood-disorders-market/1156
The prominent players in the gene therapy for blood disorders industry include:
BioMarin Pharmaceutical Inc. (U.S.), Medgenics (U.S.), Spark Therapeutics (U.S.), bluebird bio, Inc. (U.S.), Shire (U.S.), CRISPR Therapeutics (U.S.), Freeline Therapeutics (U.K.), OrphageniX (U.S.), Errant Gene Therapeutics (U.S.), Sangamo Therapeutics (U.S.), Sigilon Therapeutics, Inc. (U.S.), uniQure (Netherlands), Angiocrine Bioscience (U.S.), and Sanofi Genzyme (U.S.), and other prominent players.
Gene Therapy for Blood Disorders Market Regional Analysis:
North America is predicted to account for the largest share of the gene therapy for blood disorders market during the forecast years, followed by Europe, owing to the rising prevalence of various blood disorders, well-developed healthcare systems, and increasing R&D investments to develop effective gene therapies to treat rare diseases. According to the Hemophilia Federation of America, Hemophilia affects 1 in 5,000 male births, and around 400 babies are born with hemophilia in the U.S annually. Worldwide 400,000 individuals are living with hemophilia, and approximately 20,000 people are living with it in the United States alone.
Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1156
The Global Gene Therapy for Blood Disorders Market Segments
The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Indication
- Sickle Cell Anemia
- β-thalassemia
- Hemophilia B
- Hemophilia A
- Other Indication
The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Mechanism of Action
- Gene Therapy
- Gene Editing
The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Region
- Europe
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
North America Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
- U.S.
- Canada
Europe Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
- Germany
- Spain
- France
- Russia
- Italy
- Rest of Europe
Asia Pacific Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
- India
- Japan
- China
- Australia & New Zealand
- South Korea
Latin America Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030
- South Africa
- GCC Countries
- Rest of the Middle East & Africa
For Customised Information @ https://www.insightaceanalytic.com/customisation/1156
Other Related Reports Published by InsightAce Analytic:
Global Cell and Gene Therapy Drug Delivery Devices Market
Global Gene Therapies For Rare Diseases Market
Global Gene Therapy For Retinal Diseases Market
Global mRNA Synthesis and Manufacturing Services Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
Priyanka Tilekar
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Email: info@insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
Share this article